Peak Bio, Inc. announced that it has entered into a purchase agreements with certain existing accredited investors and institutional accredited investors of 2,500,000 common shares at a price of $10 per share for gross proceeds of $25,000,000 on April 28, 2022. The transaction will include participation from leading healthcare institutional investor, Palo Alto Investors LP and Chief Executive officer of the company Hoyoung Huh. The company expects to close the transaction concurrently with the closing of the acquisition of Ignyte Acquisition Corp.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0086 USD | +1.18% | +1.18% | -95.41% |
Mar. 05 | Akari Therapeutics, Plc entered into a definitive agreement to acquire Peak Bio, Inc.. | CI |
Feb. 16 | Peak Bio, Inc. announced that it has received $2.238 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
-95.41% | 195K | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- PKBO Stock
- News Peak Bio, Inc.
- Peak Bio, Inc. announced that it expects to receive $25 million in funding from Palo Alto Investors LP